Astrazeneca Pharma India

Stocks to watch, 10 June: Stocks like Veedol Corporation, AstraZeneca Pharma India, Force Motors, Geojit Financial Services, Tech Mahindra, ITD Cementation India, Protean eGov Technologies, Nibe, IRB Infrastructure Developers, Jana Small Finance Bank, Capri Global Capital, and Premier Energies will be in focus on June 10.

Stocks to Watch Today: Tata Motors, M&M, Niva Bupa, Alembic Pharma, IRCON, Godrej Properties, Titagarh, AstraZeneca, Genus Power, Nykaa in focus on 2 June

Stocks to Watch, 2 June: Stocks like TVS Motor Company, Eicher Motors, Hero MotoCorp, Maruti Suzuki India, Indian Energy Exchange,Indigo Paints, Manappuram Finance, Tata Motors, Mahindra and Mahindra, Niva Bupa Health Insurance Company, Alembic Pharmaceuticals, IRCON International, Godrej Properties, Titagarh Rail Systems, AstraZeneca Pharma India, Genus Power Infrastructures, and FSN E-Commerce Ventures Nykaa will be in focus on June 2.

AstraZeneca Pharma shares extend fall on fifth day; gets approval for cancer drug

AstraZeneca Pharma India Share Price | Market capitalisation stands at Rs 18,955.00 crore. The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5,000.00 on 24 March, 2025 and 08 May, 2024, respectively.

AstraZeneca Pharma shares gain 3% on CDSCO nod for expanded use of cancer drug Imfinzi

AstraZeneca Pharma share price: This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients battling advanced-stage liver cancer.

AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission

AstraZeneca Pharma India Share Price Today | The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi).

Gainers and Losers: 10 stocks that moved the most on March 27

Among sectors, auto, bank, capital goods, power, realty, telecom were up 0.5-1 percent, while metal, IT and media were down 0.3-0.5 percent

AstraZeneca India falls 0.6% despite a new CFO and nod to drug imports

AstraZeneca Pharma India shares slipped 0.6% in trade on October 3. The firm appointed a new CFO and received approval from the CDSCO to import a new drug.

AstraZeneca Pharma shares gain 3% on CDSCO approval for sale of Tremelimumab

The receipt of this permission paves way for the launch of Tremelimumab solution of 20 mg/ml in India. Tremelimumab, in combination with Durvalumab (Imfinzi), is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).

AstraZeneca Pharma gets CDSCO nod to import Enhertu for breast cancer treatment

Enhertu, an antibody-drug conjugate, is being used in the treatment of HER2-positive metastatic breast cancer in several countries. It received clearance from the European Union's drug regulator in January.

AstraZeneca India MD Gagandeep Singh Bedi resigns from post effective December 31

Bedi will be replaced by Sanjeev Panchal as additional director and also as managing director of the company with effect from January 1, 2023, AstraZeneca said in a regulatory filing.

AstraZeneca Pharma India Q1 net profit declines 45% to Rs 10.24 crore

The company had posted a net profit of Rs 18.63 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing.

AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 crore

The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing.

AstraZeneca Pharma India Q3 net profit declines 21% at Rs 21 crore

The company had posted a net profit of Rs 26.70 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing.

AstraZeneca Pharma India Q2 net profit up 83% at Rs 26 crore

The company had posted a net profit of Rs 14.41 crore for the corresponding period of the previous fiscal, it said in a filing to the BSE.

AstraZeneca Pharma India Q1 net profit declines 13% at Rs 18.63 crore

The company had posted a net profit of Rs 21.51 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a BSE filing.

AstraZeneca's Dapagliflozin gets DCGI nod for treatment of heart failure patients

The company has received import and market permission from DCGI in Form CT-20 (Marketing Authorisation- Additional Indication).

AstraZeneca Pharma India Q3 net profit down 8% to Rs 27cr

Revenue from operations stood at Rs 223.86 crore for the quarter under consideration as compared with Rs 215.19 crore for the same period a year ago.

AstraZeneca Pharma India Q4 net profit jumps threefold to Rs 9.82 cr

For the fiscal year ended March this year, the company's net profit rose to Rs 54.44 crore as against Rs 25.91 crore for the previous fiscal year.

AstraZeneca Pharma India Q2 net profit dips 67% to Rs 9.13 cr

The company had posted a net profit of Rs 27.38 crore for the corresponding period of the previous fiscal.

AstraZeneca gets marketing permission for cancer drug in India

The company has received import and market permission for Durvalumab from the Drug Controller General of India (DCGI), AstraZeneca Pharma India said in a statement.

AstraZeneca Pharma India posts Q1 net profit of Rs 2.71 cr

The company had posted a net loss of Rs 17.60 crore in the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a filing to BSE.

AstraZeneca to receive up to $26.5m grant from promoter

Drug firm AstraZeneca Pharma India today said its Sweden-based promoter -- AstraZeneca Pharmaceuticals AB -- will provide a financial grant of up to USD 26.5 million (over Rs 140 crore) to the Indian firm over the next three years.

AstraZeneca Pharma quotes ex-dividend

AstraZeneca Pharma India has recommended a dividend of Rs 3.50 per equity share of face value of Rs 2 each (175%) for the Financial Year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting.